BNP Paribas Financial Markets Acquires 12,759 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

BNP Paribas Financial Markets boosted its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 276.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 17,379 shares of the company's stock after purchasing an additional 12,759 shares during the period. BNP Paribas Financial Markets' holdings in Prestige Consumer Healthcare were worth $1,253,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. QRG Capital Management Inc. grew its holdings in shares of Prestige Consumer Healthcare by 4.7% in the second quarter. QRG Capital Management Inc. now owns 5,397 shares of the company's stock worth $372,000 after acquiring an additional 242 shares during the period. ORG Partners LLC bought a new stake in shares of Prestige Consumer Healthcare during the 2nd quarter valued at about $39,000. Robbins Farley increased its position in shares of Prestige Consumer Healthcare by 7.7% during the 2nd quarter. Robbins Farley now owns 31,480 shares of the company's stock valued at $2,167,000 after purchasing an additional 2,240 shares during the last quarter. Blue Trust Inc. lifted its stake in shares of Prestige Consumer Healthcare by 106.9% in the 2nd quarter. Blue Trust Inc. now owns 867 shares of the company's stock worth $63,000 after purchasing an additional 448 shares during the period. Finally, Gladius Capital Management LP bought a new position in shares of Prestige Consumer Healthcare in the 2nd quarter worth approximately $35,000. Institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Price Performance

Shares of NYSE PBH traded up $0.97 during midday trading on Tuesday, reaching $84.25. The stock had a trading volume of 375,918 shares, compared to its average volume of 251,839. The company has a market capitalization of $4.16 billion, a price-to-earnings ratio of 20.50, a price-to-earnings-growth ratio of 2.37 and a beta of 0.49. Prestige Consumer Healthcare Inc. has a 12-month low of $57.95 and a 12-month high of $86.36. The stock has a 50-day moving average of $77.27 and a 200-day moving average of $72.19. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The business had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. During the same quarter in the prior year, the business posted $1.07 EPS. Prestige Consumer Healthcare's revenue for the quarter was down .9% compared to the same quarter last year. As a group, research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.44 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total value of $743,166.00. Following the sale, the executive vice president now directly owns 18,365 shares of the company's stock, valued at approximately $1,505,930. The trade was a 33.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Ronald M. Lombardi sold 10,875 shares of the business's stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the sale, the chief executive officer now owns 320,952 shares in the company, valued at $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 38,810 shares of company stock valued at $3,187,300. Corporate insiders own 1.60% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on PBH. Sidoti cut shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 target price for the company. in a report on Monday. DA Davidson restated a "buy" rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Finally, Jefferies Financial Group reaffirmed a "hold" rating and issued a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of "Moderate Buy" and a consensus target price of $85.25.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.